The FDA Center for Drug Evaluation and Research turned in its 13th novel approval of 2022 on Friday the 13th when it cleared Eli Lilly and Company’s dual-targeted type 2 diabetes therapy Mounjaro (tirzepatide).
Mounjaro marks the first drug in a new class of medicines that activate both the glucagon-like peptide-1 (GLP-1) and glucose-dependent
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?